Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 3 art units • 3 examiners • 0 of 5 (0%) have an AI response strategy ready
Labrador Diagnostics LLC has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters span 3 distinct examiners and 3 distinct art units, creating multiple prosecution contexts for response planning.
MONTGOMERY, ANN Y is the busiest examiner, with 3 pending matters. The concentration of matters with that examiner makes consistent argument development useful, while the remaining matters require separate examiner-specific analysis.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTGOMERY, ANN Y | 3 | 69.1% | +27.6% |
| GIERE, REBECCA M | 1 | 73.7% | +32.3% |
| TURK, NEIL N | 1 | 51.0% | +44.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 13647325 | POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF | TURK, NEIL N | 98d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 13647325 | POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF | TURK, NEIL N | 98d overdue |
| 14848032 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF | MONTGOMERY, ANN Y | 17d overdue |
| 17165249 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF | MONTGOMERY, ANN Y | — |
| 17007334 | SYSTEMS AND METHODS FOR CONDUCTING ANIMAL STUDIES | GIERE, REBECCA M | — |
| 14963030 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF | MONTGOMERY, ANN Y | — |
| Art Unit | Apps |
|---|---|
| 1678 | 3 |
| 1677 | 1 |
| 1798 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17165249 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF | MONTGOMERY, ANN Y | 1678 | §103 | Non-Final OA | — | Pending | Feb 02, 2021 |
| 17007334 | SYSTEMS AND METHODS FOR CONDUCTING ANIMAL STUDIES | GIERE, REBECCA M | 1677 | §112DP | Final Rejection | — | Pending | Aug 31, 2020 |
| 14963030 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF | MONTGOMERY, ANN Y | 1678 | §112 | Non-Final OA | — | Pending | Dec 08, 2015 |
| 14848032 | MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF | MONTGOMERY, ANN Y | 1678 | §112 | Final Rejection | 17d overdue | Pending | Sep 08, 2015 |
| 13647325 | POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF | TURK, NEIL N | 1798 | §103§112 | Final Rejection | 98d overdue | Pending | Oct 08, 2012 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLabrador Diagnostics LLC has 5 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Ann Y Montgomery has the most, with 3 of Labrador Diagnostics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
